Core Viewpoint - Company has received approval from the National Medical Products Administration for the expanded age range of its meningococcal polysaccharide conjugate vaccine, MCV4, from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children" [1] Group 1 - The product, known as Manhaixin®, is China's first quadrivalent meningococcal conjugate vaccine, which helps bridge the gap in this field between China and developed countries [1] - The approval fills a significant gap in the availability of high-end vaccines in China, providing a better solution for the prevention of meningococcal disease in children aged 6 years and below [1] - Manhaixin® has demonstrated strong market performance and an increasing market share due to its innovative advantages [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for an expanded age range for its meningococcal polysaccharide conjugate vaccine, MCV4, from children aged 3 months to 3 years to children aged 3 months to 6 years [1] Group 1 - The approval allows the company's product, MCV4 (marketed as Manhaixin®), to be administered to a broader age group, enhancing its market potential [1] - Manhaixin® is the first quadrivalent meningococcal conjugate vaccine in China, addressing the gap in high-end vaccines in the country and reducing the disparity with developed nations [1] - The vaccine provides a superior solution for the prevention of meningococcal disease in children aged 6 years and below, showcasing strong market performance and increasing market share [1]